Opsona and CSL strike infectious disease and cancer deal
This article was originally published in Scrip
Executive Summary
Opsona Therapeutics and CSL, the world's second largest plasma products company, are to identify novel vaccine adjuvant formulations for infectious diseases and certain cancers.